Jasper Therapeutics, Inc. 8-K

What Happened
Jasper Therapeutics, Inc. (JSPR) filed an 8-K saying it received a Nasdaq notice on June 3, 2026 that its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq has given the company a 180-calendar-day cure period (until November 30, 2026) to regain compliance by having the stock close at $1.00 or more for at least ten consecutive business days. The notice does not affect current listing or trading — JSPR and its public warrants will continue to trade on Nasdaq under symbols "JSPR" and "JSPRW."

Key Details

• Notice date: June 3, 2026; deficiency based on 30 consecutive business days below $1.00.
• Cure period: 180 calendar days, until November 30, 2026; compliance requires a $1.00+ close for 10 consecutive business days.
• If not cured, the company may be eligible for a second 180-day period only if it meets market value and other initial listing standards (except the bid-price), and notifies Nasdaq it will cure (potentially via a reverse stock split).
• No immediate trading or listing suspension; Nasdaq could later notify the company of delisting eligibility and the company may appeal.

Why It Matters
A prolonged low share price could put JSPR at risk of delisting if the company cannot meet Nasdaq’s bid-price rule or obtain relief. Delisting would make the stock harder to trade and could harm liquidity and investor confidence. The company says it will monitor the bid price and consider options (including a reverse stock split) but provides no assurance it will regain compliance. Investors should watch the stock’s trading price and future announcements about any cure actions or Nasdaq communications.